BAQSIMI

This brand name is authorized in United States. It is also authorized in Austria, Canada, Croatia, Cyprus, Estonia, Finland, France, Ireland, Japan, Lithuania, Netherlands, Poland, Romania, Spain.

Active ingredients

The drug BAQSIMI contains one active pharmaceutical ingredient (API):

1	Glucagon UNII 1H87NVF4DB - GLUCAGON HYDROCHLORIDE
	Glucagon is a hyperglycaemic agent that mobilises hepatic glycogen, which is released into the blood as glucose. Glucagon inhibits the tone and motility of the smooth muscle in the gastrointestinal tract.
	Read more about Glucagon

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
H04AA01	Glucagon	H Systemic hormonal preparations, excl. Sex hormones and insulins → H04 Pancreatic hormones → H04A Glycogenolytic hormones → H04AA Glycogenolytic hormones
Discover more medicines within H04AA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02492415
EE	Ravimiamet	1809176, 1809187
ES	Centro de información online de medicamentos de la AEMPS	1191406001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	129450
FR	Base de données publique des médicaments	67972497
JP	医薬品医療機器総合機構	2492700R1022
LT	Valstybinė vaistų kontrolės tarnyba	1089151, 1089152
NL	Z-Index G-Standaard, PRK	205079
PL	Rejestru Produktów Leczniczych	100411390
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W66520001, W66520002
US	FDA, National Drug Code	0002-6145